Latest updates demonstrate commitment to customers and market leadership of Phoenix Platform
新泽西州普林斯顿- 2023 年 6 月 12 日快讯。Certara®, the global leader in biosimulation, today announced the launch of version 8.4 of its Phoenix™ platform, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. Version 8.4 delivers new features driven by customer demand that improve efficiency, quality, and speed.
Key Phoenix 8.4 updates include the following:
- Usability Enhancements: Scientists will find a number of improvements focused on making Phoenix more intuitive and streamlined. For example, duplicating objects within a workflow is a convenience that will save time and allow PK experts to work more effectively.
- Auditability Improvements: Certara understands the importance of maintaining a robust audit trail. Phoenix 8.4 的可审计性特性之一是能够针对日期/时间格式轻松地设置 UTC 或系统时区的用户首选项。
- Compatibility Upgrades: 该版本使 Phoenix 比以往任何时候都具有更大的兼容性。例如，Phoenix 8.4 现在支持更多的数据文件类型，包括 sas7bdat 文件和 SAS 传输文件 (XPT) 格式（直至 V9）。
These enhancements extend to various aspects of the software, including the Phoenix Platform, Reporting, Charting, and NLME. The updates are expected to significantly enhance the Phoenix user’s ability to analyze, interpret, and visualize data.
About Phoenix
The Phoenix platform is used worldwide by more than 6,000 scientists at biopharmaceutical companies, academic and non-profit institutions, and regulatory agencies. Eleven regulatory agencies, including the U.S. FDA, PMDA in Japan, and NMPA in China, rely on Phoenix to evaluate life-saving drug candidates.
For more information on the Phoenix platform, please https://www.certara.com/software/phoenix-pkpd/.
关于Certara
http://www.certara.com/ Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. 其客户包括超 2,000 家生物制药公司、学术机构和来自 62 个国家的监管机构。
